A single production facility capable of handling multiple radionuclide species—from positron-emitting diagnostics to alpha-emitting therapeutics—represents the cornerstone of modern nuclear medicine manufacturing. Protheragen delivers integrated multi-nuclide cGMP production line services that bridge the gap between radiochemical innovation and commercial-ready supply, empowering sponsors to advance theranostic programs with confidence.
Multi-nuclide GMP production refers to the capability of manufacturing radiopharmaceuticals using diverse radionuclides—spanning alpha emitters, beta emitters, and positron/gamma emitters—within a single, compliant facility infrastructure. Unlike conventional pharmaceutical manufacturing, radiopharmaceutical production demands specialized shielded enclosures, remote handling systems, and time-critical workflows due to the radioactive decay of isotopes. A multi-nuclide approach enables facilities to pivot across diagnostic and therapeutic applications, accommodating isotopes with half-lives ranging from minutes to weeks while maintaining stringent quality standards. This flexibility is particularly vital in the era of theranostics, where paired diagnostic and therapeutic agents—often labeled with different radionuclides—must be produced under harmonized conditions to ensure consistent targeting vectors and comparable pharmacokinetic profiles.
Fig 1. Schematic diagram of the radiopharmacy facility layout, including the radiochemistry laboratory (E20), cleanroom system (E20A-C), as well as the hot cells, biosafety cabinets, tables, and shelves. (Asor, Angela, et al., 2024)
The design of a multi-nuclide production line integrates radiation protection from the ground up, rather than retrofitting standard pharmaceutical infrastructure. Shielded hot cells, automated synthesis modules, and specialized ventilation systems are configured to handle varying emission energies and physical states of different isotopes. From cyclotron-produced gallium-68 and fluorine-18 for PET imaging, to reactor- or accelerator-derived lutetium-177 for beta-targeted radionuclide therapy, and actinium-225 for emerging alpha-targeted applications, each nuclide imposes unique handling requirements. The convergence of these capabilities within one cGMP environment reduces cross-contamination risks, streamlines technology transfer, and accelerates the path from preclinical proof-of-concept to commercial batch release.
The theranostic paradigm—combining diagnostic imaging with targeted therapy using the same molecular vector—has redefined precision oncology. This approach enables clinicians to visualize tumor expression of specific targets before administering therapeutic radionuclides, thereby selecting appropriate patients and predicting treatment response. The table below summarizes the current landscape of key radionuclide pairs and their respective roles in nuclear medicine:
| Radionuclide | Emission Type | Primary Application | Half-Life |
|---|---|---|---|
| Gallium-68 (Ga-68) | Positron (β+) | PET imaging for patient selection and staging | 68 minutes |
| Lutetium-177 (Lu-177) | Beta (β−) + gamma | Targeted radionuclide therapy (PRRT, PSMA-RLT) | 6.7 days |
| Actinium-225 (Ac-225) | Alpha (α) | Targeted alpha therapy for resistant metastases | 10 days |
| Fluorine-18 (F-18) | Positron (β+) | Oncology and neurology PET imaging | 109.8 minutes |
| Copper-64 (Cu-64) | Positron (β+) + beta | Long-half-life PET imaging and theranostics | 12.7 hours |
| Zirconium-89 (Zr-89) | Positron (β+) | Immuno-PET for antibody pharmacokinetics | 78.4 hours |
| Terbium-161 (Tb-161) | Beta (β−) + Auger | Next-generation targeted radionuclide therapy | 6.9 days |
| Astatine-211 (At-211) | Alpha (α) | Preclinical and early clinical targeted alpha therapy | 7.2 hours |
Protheragen stands at the intersection of radiopharmaceutical innovation and commercial manufacturing excellence. Through our multi-nuclide cGMP production lines, we offer end-to-end capabilities that encompass process development, radiolabeling optimization, aseptic fill-finish, and batch release—tailored to the unique decay properties and handling requirements of each radionuclide. Whether your program requires beta-emitting lutetium-177 for radioligand therapy, gallium-68 for companion diagnostic imaging, or next-generation alpha emitters for targeted alpha therapy, our integrated infrastructure and experienced radiochemistry team ensure seamless translation from clinical supply to commercial-scale production.
Our multi-nuclide production workflow is engineered to synchronize radiochemical precision with pharmaceutical compliance, ensuring that each batch meets quality specifications while accounting for radioactive decay. The process unfolds through six integrated stages, from raw isotope receipt to final dose distribution.
Incoming radionuclides—whether from cyclotron, reactor, or generator—undergo immediate radiochemical purification within shielded hot cells. The isotope is separated from target material, converted to a reactive chemical form, and qualified for purity before entering the manufacturing stream.
The targeting vector (peptide, antibody, or small molecule) is conjugated with the appropriate chelator or prosthetic group. Automated synthesis modules perform the radiolabeling reaction under controlled temperature, pH, and time parameters, with real-time monitoring of radioactivity profiles.
Crude reaction mixtures are purified using solid-phase extraction, HPLC, or ion-exchange chromatography to remove unbound radionuclide and impurities. The purified radiopharmaceutical is then formulated in a sterile, pyrogen-free buffer suitable for in vitro and in vivo stability.
The formulated product is transferred to a Grade A isolator for aseptic filling into vials or syringes. Each unit is assayed for total activity and activity concentration, then sealed in lead-shielded containers with radiation trefoil labeling and transport documentation.
Samples undergo comprehensive QC testing including radiochemical purity, radionuclidic identity, pH, osmolality, sterility, and endotoxin assessment. A qualified person reviews manufacturing records and QC data to authorize batch release, often within hours to accommodate short half-lives.
Released doses are dispatched via specialized radiopharmaceutical logistics networks, with delivery timed to clinical administration schedules. Chain-of-custody documentation ensures traceability from production batch to individual patient dose.
Ready to advance your radiopharmaceutical program from concept to commercial supply? Reach out to us today to discuss your multi-nuclide production requirements, reserve manufacturing capacity, or explore our integrated CRDMO and CRO solutions. Our team of radiochemistry and regulatory experts is prepared to design a tailored manufacturing strategy that aligns with your clinical timeline and commercial objectives. Contact us now and discover how Protheragen can accelerate your path to precision nuclear medicine.
Reference